
Protalix BioTherapeutics Investor Relations Material
Latest events

Q2 2025
Protalix BioTherapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Protalix BioTherapeutics Inc
Access all reports
Protalix BioTherapeutics Inc. is a biopharmaceutical company focusing on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based protein expression system. This technology enables the company to produce proteins with clinically improved profiles and to develop a pipeline of proprietary therapeutic proteins aimed at established pharmaceutical markets. Additionally, the company is developing other products, including treatments for cystic fibrosis and Fabry Disease, utilizing its platform to manufacture complex proteins, antibodies, and vaccines. The company is headquartered in Carmiel, Israel, and its shares are listed on the NYSE.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
PLX
Country
🇺🇸 United States